Market Outlook
The global PD-L1 and PIK3CA Testing market size was valued at USD 536.9 million in 2022 and is forecast to a readjusted size of USD 1892 million by 2029 with a CAGR of 19.7% during review period.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations. PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market. PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application. North America is the largest consumption place, with a market share nearly 57%. Following North America, Europe is the second largest consumption place with the market share of 28%. Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.
This report is a detailed and comprehensive analysis for global PD-L1 and PIK3CA Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PD-L1 and PIK3CA Testing market size and forecasts, in consumption value ($ Million), 2018-2029
Global PD-L1 and PIK3CA Testing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global PD-L1 and PIK3CA Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global PD-L1 and PIK3CA Testing market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-L1 and PIK3CA Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-L1 and PIK3CA Testing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Agilent Technologies
Roche
QIAGEN
EntroGen
Amoy Diagnostics
ACCB Biotech
Segmentation By Type
PD-L1 Testing
PIK3CA Testing
Segmentation By Application
Hospital
Diagnostic Center
Others
Segmentation By Region
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the PD-L1 and PIK3CA testing market in 2025?
The strengths include the growing acceptance of personalized medicine, which enhances the demand for biomarker testing. Additionally, advances in diagnostic technologies and increased funding for cancer research support the development and accessibility of these tests.
What are the weaknesses of the PD-L1 and PIK3CA testing market in 2025?
Weaknesses encompass the high costs associated with advanced testing procedures, which may limit access for some patients. There is also a lack of standardization in testing methods, leading to variability in results and potential confusion among healthcare providers.
What opportunities exist in the PD-L1 and PIK3CA testing market in 2025?
Opportunities lie in the potential for expanded applications of testing across various cancer types, as well as the increasing collaboration between diagnostic companies and pharmaceutical firms to develop companion diagnostics. Emerging markets also present growth potential as awareness of biomarker testing rises.
What threats could impact the PD-L1 and PIK3CA testing market in 2025?
Threats include regulatory challenges that may arise from new testing guidelines and reimbursement issues that could affect market access. Additionally, competition from alternative therapies and diagnostic approaches could hinder market growth.
Market PESTEL Analysis
What political factors influence the PD-L1 and PIK3CA testing market in 2025?
Political factors include government policies on healthcare funding and reimbursement for diagnostic tests, which directly affect the affordability and accessibility of PD-L1 and PIK3CA testing. Additionally, political support for cancer research and healthcare reforms can drive market growth.
How do economic factors impact the PD-L1 and PIK3CA testing market in 2025?
Economic factors such as healthcare spending, the affordability of tests, and the economic stability of countries influence market demand. High costs of testing may limit access in low-income regions, while economic growth can increase healthcare investment in advanced diagnostics.
What social factors shape the PD-L1 and PIK3CA testing market in 2025?
Social factors include increasing awareness of personalized medicine and cancer biomarker testing, leading to higher patient demand. Furthermore, the aging population and rising cancer incidence globally drive the need for innovative diagnostic solutions like PD-L1 and PIK3CA testing.
What technological factors affect the PD-L1 and PIK3CA testing market in 2025?
Technological advancements in genomics and molecular diagnostics are critical drivers for the market. Newer, more accurate testing technologies, such as next-generation sequencing, can improve the precision of PD-L1 and PIK3CA testing, making them more accessible and effective in clinical settings.
What environmental factors impact the PD-L1 and PIK3CA testing market in 2025?
Environmental factors may have a smaller direct impact on the PD-L1 and PIK3CA testing market, but growing concerns over sustainable healthcare practices and the environmental footprint of diagnostic technologies could influence the development and use of eco-friendly testing solutions.
What legal factors affect the PD-L1 and PIK3CA testing market in 2025?
Legal factors include the evolving regulatory landscape for cancer diagnostics, with new guidelines and approvals required for test validation and commercialization. Intellectual property rights, data privacy laws, and regulations related to test approval can also affect the market dynamics.
Market SIPOC Analysis
Who are the suppliers in the PD-L1 and PIK3CA testing market in 2025?
Suppliers include biotech and pharmaceutical companies that develop and manufacture diagnostic kits, reagents, and testing platforms. Additionally, research institutions and laboratories that contribute to the development of new testing technologies play a key role.
What inputs are necessary for the PD-L1 and PIK3CA testing market in 2025?
Key inputs include high-quality biological samples (e.g., tissue biopsies), advanced diagnostic technology such as next-generation sequencing platforms, reagents, and skilled healthcare professionals to interpret test results. Research and clinical trial data also provide valuable insights.
What processes are involved in the PD-L1 and PIK3CA testing market in 2025?
Processes involve sample collection, preparation, and analysis through molecular diagnostics platforms. Testing procedures such as immunohistochemistry (IHC) for PD-L1 and genetic sequencing for PIK3CA mutations are used to identify biomarkers. Data analysis and result interpretation are crucial to ensuring accuracy.
What are the outputs of the PD-L1 and PIK3CA testing market in 2025?
Outputs include test results that identify the presence or absence of specific biomarkers, helping clinicians make informed decisions on cancer treatment plans. These results enable personalized therapies and are essential in clinical trials and companion diagnostics.
Who are the customers in the PD-L1 and PIK3CA testing market in 2025?
Customers include hospitals, cancer treatment centers, pharmaceutical companies conducting clinical trials, healthcare providers, and patients seeking personalized cancer treatment options. Regulatory agencies also play a role as they evaluate test efficacy and approval.
Market Porter's Five Forces
How intense is the threat of new entrants in the PD-L1 and PIK3CA testing market in 2025?
The threat of new entrants is moderate. While the high cost of developing diagnostic tests and the need for regulatory approvals can be barriers, the increasing demand for personalized medicine and advancements in technology create opportunities for new companies to enter the market, especially with innovative solutions.
How strong is the bargaining power of suppliers in the PD-L1 and PIK3CA testing market in 2025?
The bargaining power of suppliers is moderate to high. Key suppliers of reagents, diagnostic platforms, and testing technology hold significant influence, especially as there are a limited number of companies that can provide specialized materials needed for these tests. However, increasing competition in the supply chain could potentially reduce this power.
How strong is the bargaining power of buyers in the PD-L1 and PIK3CA testing market in 2025?
The bargaining power of buyers is moderate. While healthcare providers and patients benefit from the growing availability of diagnostic tests, the costs associated with these tests and the need for regulatory approval limit their ability to negotiate prices. Additionally, the niche nature of these tests gives providers some leverage.
What is the threat of substitute products or services in the PD-L1 and PIK3CA testing market in 2025?
The threat of substitutes is low to moderate. While alternative diagnostic methods exist, such as traditional pathology assessments or different biomarker tests, PD-L1 and PIK3CA testing remain central to personalized cancer treatment. As research and innovation continue, newer alternatives could arise, but they would need to prove comparable in accuracy and efficacy.
How intense is the competitive rivalry in the PD-L1 and PIK3CA testing market in 2025?
The competitive rivalry is high. The market is dominated by a few major diagnostic companies, while several smaller players and research labs are entering the space. The increasing demand for precision medicine and the race to develop more efficient, cost-effective, and accurate testing technologies heightens competition among key players.
Market Upstream Analysis
What are the key upstream factors impacting the PD-L1 and PIK3CA testing market in 2025?
Key upstream factors include the availability of advanced research in genomics and molecular biology, which drives the development of new testing platforms. The quality of raw materials, such as antibodies and genetic sequencing technologies, also plays a crucial role in the accuracy and reliability of the tests.
How does the supply chain affect the PD-L1 and PIK3CA testing market in 2025?
The supply chain is heavily influenced by the availability of specialized reagents, testing kits, and diagnostic technologies, which are often sourced from a few large suppliers. Any disruptions in the supply chain, such as shortages of critical materials or delays in production, could impact the testing market’s efficiency and growth.
What role does research and development (R&D) play in the PD-L1 and PIK3CA testing market in 2025?
R&D is a critical upstream factor, as continuous innovation leads to the development of more accurate, efficient, and cost-effective testing methods. Investment in R&D by biotech firms and academic institutions helps in improving the precision of PD-L1 and PIK3CA testing, contributing to better patient outcomes and market expansion.
How do regulatory approvals influence the PD-L1 and PIK3CA testing market in 2025?
Regulatory approvals from bodies like the FDA and EMA are essential upstream drivers. These approvals ensure that testing technologies are validated for clinical use and that they meet safety and efficacy standards. Delays or changes in regulations can impact the pace at which new tests reach the market and influence the overall growth of the market.
What are the challenges faced by upstream suppliers in the PD-L1 and PIK3CA testing market in 2025?
Upstream suppliers face challenges related to high production costs, the complexity of developing precise diagnostic tools, and the regulatory hurdles involved in obtaining approvals for new products. Additionally, there is increasing pressure to meet global demand while ensuring the consistency and quality of materials used in testing.
Market Midstream Analysis
What are the key midstream factors affecting the PD-L1 and PIK3CA testing market in 2025?
Midstream factors include the distribution and logistics of testing kits, reagents, and diagnostic platforms to healthcare providers. The availability and accessibility of trained professionals to conduct these tests and interpret results also play a crucial role in ensuring the effective delivery of these services.
How does technology integration impact the PD-L1 and PIK3CA testing market in 2025?
Technology integration is a significant midstream factor, as the ability to efficiently incorporate cutting-edge technologies like next-generation sequencing (NGS) into testing procedures directly impacts the accuracy and speed of results. Automation in testing and data processing is also essential for scaling up the delivery of these tests.
What role do healthcare providers play in the PD-L1 and PIK3CA testing market in 2025?
Healthcare providers, including hospitals, diagnostic labs, and oncologists, are integral to the midstream segment. They are responsible for administering the tests, interpreting the results, and incorporating the findings into treatment plans. Their adoption of PD-L1 and PIK3CA testing will significantly influence market growth.
What challenges do midstream players face in the PD-L1 and PIK3CA testing market in 2025?
Midstream players face challenges such as the need for highly trained personnel to perform specialized tests and the complexities of managing logistics, especially when it comes to delivering time-sensitive diagnostic results. Additionally, maintaining high standards for test accuracy and overcoming barriers in reimbursement can also hinder market growth.
How does market competition among midstream players affect the PD-L1 and PIK3CA testing market in 2025?
The competition among midstream players, such as laboratories and testing service providers, is likely to intensify. This drives innovation in test accuracy, cost-efficiency, and turnaround time. However, it may also lead to pricing pressure, where companies must balance cost reductions with maintaining quality services.
Market Downstream Analysis
What are the key downstream factors affecting the PD-L1 and PIK3CA testing market in 2025?
Downstream factors include the implementation of test results in clinical treatment decisions, particularly in oncology. The market is influenced by the adoption of precision medicine by healthcare providers and patients, as well as the demand for personalized treatment plans based on biomarker testing.
How do patient access and demand influence the PD-L1 and PIK3CA testing market in 2025?
Patient access and demand play a significant role in shaping the downstream market. As awareness of precision medicine grows, more patients seek personalized treatment options. However, patient access may be limited by test affordability and availability, particularly in regions with less access to advanced diagnostics.
What role do insurance and reimbursement policies play in the PD-L1 and PIK3CA testing market in 2025?
Insurance and reimbursement policies have a significant downstream impact. The level of reimbursement for PD-L1 and PIK3CA testing directly affects the affordability and accessibility of these tests for patients. Policies that favor reimbursement for biomarker tests can drive wider adoption, while restrictive policies may limit access.
How do healthcare providers' adoption rates impact the PD-L1 and PIK3CA testing market in 2025?
Healthcare providers’ adoption of these tests directly impacts the downstream market. Hospitals, oncologists, and treatment centers that integrate PD-L1 and PIK3CA testing into their clinical practices will drive demand. However, providers' reluctance to adopt these tests due to cost or lack of training can hinder market growth.
What are the challenges faced by downstream players in the PD-L1 and PIK3CA testing market in 2025?
Downstream players face challenges such as navigating complex reimbursement landscapes, managing patient demand, and ensuring consistent access to high-quality testing services. Additionally, there may be challenges in educating both healthcare providers and patients about the importance and availability of biomarker testing.
Chapter 1, to describe PD-L1 and PIK3CA Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-L1 and PIK3CA Testing, with revenue, gross margin and global market share of PD-L1 and PIK3CA Testing from 2018 to 2023.
Chapter 3, the PD-L1 and PIK3CA Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and PD-L1 and PIK3CA Testing market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-L1 and PIK3CA Testing.
Chapter 13, to describe PD-L1 and PIK3CA Testing research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of PD-L1 and PIK3CA Testing
1.2 Market Estimation Caveats and Base Year
1.3 Classification of PD-L1 and PIK3CA Testing by Type
1.3.1 Overview: Global PD-L1 and PIK3CA Testing Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global PD-L1 and PIK3CA Testing Consumption Value Market Share by Type in 2022
1.3.3 PD-L1 Testing
1.3.4 PIK3CA Testing
1.4 Global PD-L1 and PIK3CA Testing Market by Application
1.4.1 Overview: Global PD-L1 and PIK3CA Testing Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Diagnostic Center
1.4.4 Others
1.5 Global PD-L1 and PIK3CA Testing Market Size & Forecast
1.6 Global PD-L1 and PIK3CA Testing Market Size and Forecast by Region
1.6.1 Global PD-L1 and PIK3CA Testing Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global PD-L1 and PIK3CA Testing Market Size by Region, (2018-2029)
1.6.3 North America PD-L1 and PIK3CA Testing Market Size and Prospect (2018-2029)
1.6.4 Europe PD-L1 and PIK3CA Testing Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific PD-L1 and PIK3CA Testing Market Size and Prospect (2018-2029)
1.6.6 South America PD-L1 and PIK3CA Testing Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa PD-L1 and PIK3CA Testing Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Agilent Technologies
2.1.1 Agilent Technologies Details
2.1.2 Agilent Technologies Major Business
2.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Product and Solutions
2.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Agilent Technologies Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche PD-L1 and PIK3CA Testing Product and Solutions
2.2.4 Roche PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Roche Recent Developments and Future Plans
2.3 QIAGEN
2.3.1 QIAGEN Details
2.3.2 QIAGEN Major Business
2.3.3 QIAGEN PD-L1 and PIK3CA Testing Product and Solutions
2.3.4 QIAGEN PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 QIAGEN Recent Developments and Future Plans
2.4 EntroGen
2.4.1 EntroGen Details
2.4.2 EntroGen Major Business
2.4.3 EntroGen PD-L1 and PIK3CA Testing Product and Solutions
2.4.4 EntroGen PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 EntroGen Recent Developments and Future Plans
2.5 Amoy Diagnostics
2.5.1 Amoy Diagnostics Details
2.5.2 Amoy Diagnostics Major Business
2.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Product and Solutions
2.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amoy Diagnostics Recent Developments and Future Plans
2.6 ACCB Biotech
2.6.1 ACCB Biotech Details
2.6.2 ACCB Biotech Major Business
2.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Product and Solutions
2.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 ACCB Biotech Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PD-L1 and PIK3CA Testing Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of PD-L1 and PIK3CA Testing by Company Revenue
3.2.2 Top 3 PD-L1 and PIK3CA Testing Players Market Share in 2022
3.2.3 Top 6 PD-L1 and PIK3CA Testing Players Market Share in 2022
3.3 PD-L1 and PIK3CA Testing Market: Overall Company Footprint Analysis
3.3.1 PD-L1 and PIK3CA Testing Market: Region Footprint
3.3.2 PD-L1 and PIK3CA Testing Market: Company Product Type Footprint
3.3.3 PD-L1 and PIK3CA Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global PD-L1 and PIK3CA Testing Consumption Value and Market Share by Type (2018-2023)
4.2 Global PD-L1 and PIK3CA Testing Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global PD-L1 and PIK3CA Testing Consumption Value Market Share by Application (2018-2023)
5.2 Global PD-L1 and PIK3CA Testing Market Forecast by Application (2024-2029)
6 North America
6.1 North America PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2029)
6.2 North America PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2029)
6.3 North America PD-L1 and PIK3CA Testing Market Size by Country
6.3.1 North America PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2029)
6.3.2 United States PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
6.3.3 Canada PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
6.3.4 Mexico PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2029)
7.2 Europe PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2029)
7.3 Europe PD-L1 and PIK3CA Testing Market Size by Country
7.3.1 Europe PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2029)
7.3.2 Germany PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
7.3.3 France PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
7.3.4 United Kingdom PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
7.3.5 Russia PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
7.3.6 Italy PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2029)
8.2 Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2029)
8.3 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Region
8.3.1 Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Region (2018-2029)
8.3.2 China PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
8.3.3 Japan PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
8.3.4 South Korea PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
8.3.5 India PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
8.3.7 Australia PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
9 South America
9.1 South America PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2029)
9.2 South America PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2029)
9.3 South America PD-L1 and PIK3CA Testing Market Size by Country
9.3.1 South America PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2029)
9.3.2 Brazil PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
9.3.3 Argentina PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2029)
10.2 Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2029)
10.3 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country
10.3.1 Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2029)
10.3.2 Turkey PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
10.3.4 UAE PD-L1 and PIK3CA Testing Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 PD-L1 and PIK3CA Testing Market Drivers
11.2 PD-L1 and PIK3CA Testing Market Restraints
11.3 PD-L1 and PIK3CA Testing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 PD-L1 and PIK3CA Testing Industry Chain
12.2 PD-L1 and PIK3CA Testing Upstream Analysis
12.3 PD-L1 and PIK3CA Testing Midstream Analysis
12.4 PD-L1 and PIK3CA Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global PD-L1 and PIK3CA Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PD-L1 and PIK3CA Testing Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global PD-L1 and PIK3CA Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global PD-L1 and PIK3CA Testing Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 6. Agilent Technologies Major Business
Table 7. Agilent Technologies PD-L1 and PIK3CA Testing Product and Solutions
Table 8. Agilent Technologies PD-L1 and PIK3CA Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Agilent Technologies Recent Developments and Future Plans
Table 10. Roche Company Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche PD-L1 and PIK3CA Testing Product and Solutions
Table 13. Roche PD-L1 and PIK3CA Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Roche Recent Developments and Future Plans
Table 15. QIAGEN Company Information, Head Office, and Major Competitors
Table 16. QIAGEN Major Business
Table 17. QIAGEN PD-L1 and PIK3CA Testing Product and Solutions
Table 18. QIAGEN PD-L1 and PIK3CA Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. QIAGEN Recent Developments and Future Plans
Table 20. EntroGen Company Information, Head Office, and Major Competitors
Table 21. EntroGen Major Business
Table 22. EntroGen PD-L1 and PIK3CA Testing Product and Solutions
Table 23. EntroGen PD-L1 and PIK3CA Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. EntroGen Recent Developments and Future Plans
Table 25. Amoy Diagnostics Company Information, Head Office, and Major Competitors
Table 26. Amoy Diagnostics Major Business
Table 27. Amoy Diagnostics PD-L1 and PIK3CA Testing Product and Solutions
Table 28. Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Amoy Diagnostics Recent Developments and Future Plans
Table 30. ACCB Biotech Company Information, Head Office, and Major Competitors
Table 31. ACCB Biotech Major Business
Table 32. ACCB Biotech PD-L1 and PIK3CA Testing Product and Solutions
Table 33. ACCB Biotech PD-L1 and PIK3CA Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. ACCB Biotech Recent Developments and Future Plans
Table 35. Global PD-L1 and PIK3CA Testing Revenue (USD Million) by Players (2018-2023)
Table 36. Global PD-L1 and PIK3CA Testing Revenue Share by Players (2018-2023)
Table 37. Breakdown of PD-L1 and PIK3CA Testing by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in PD-L1 and PIK3CA Testing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key PD-L1 and PIK3CA Testing Players
Table 40. PD-L1 and PIK3CA Testing Market: Company Product Type Footprint
Table 41. PD-L1 and PIK3CA Testing Market: Company Product Application Footprint
Table 42. PD-L1 and PIK3CA Testing New Market Entrants and Barriers to Market Entry
Table 43. PD-L1 and PIK3CA Testing Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global PD-L1 and PIK3CA Testing Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global PD-L1 and PIK3CA Testing Consumption Value Share by Type (2018-2023)
Table 46. Global PD-L1 and PIK3CA Testing Consumption Value Forecast by Type (2024-2029)
Table 47. Global PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2023)
Table 48. Global PD-L1 and PIK3CA Testing Consumption Value Forecast by Application (2024-2029)
Table 49. North America PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America PD-L1 and PIK3CA Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America PD-L1 and PIK3CA Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America PD-L1 and PIK3CA Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe PD-L1 and PIK3CA Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe PD-L1 and PIK3CA Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe PD-L1 and PIK3CA Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America PD-L1 and PIK3CA Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America PD-L1 and PIK3CA Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America PD-L1 and PIK3CA Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa PD-L1 and PIK3CA Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 79. PD-L1 and PIK3CA Testing Raw Material
Table 80. Key Suppliers of PD-L1 and PIK3CA Testing Raw Materials
List of Figures
Figure 1. PD-L1 and PIK3CA Testing Picture
Figure 2. Global PD-L1 and PIK3CA Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PD-L1 and PIK3CA Testing Consumption Value Market Share by Type in 2022
Figure 4. PD-L1 Testing
Figure 5. PIK3CA Testing
Figure 6. Global PD-L1 and PIK3CA Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. PD-L1 and PIK3CA Testing Consumption Value Market Share by Application in 2022
Figure 8. Hospital Picture
Figure 9. Diagnostic Center Picture
Figure 10. Others Picture
Figure 11. Global PD-L1 and PIK3CA Testing Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global PD-L1 and PIK3CA Testing Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market PD-L1 and PIK3CA Testing Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global PD-L1 and PIK3CA Testing Consumption Value Market Share by Region (2018-2029)
Figure 15. Global PD-L1 and PIK3CA Testing Consumption Value Market Share by Region in 2022
Figure 16. North America PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 19. South America PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. Global PD-L1 and PIK3CA Testing Revenue Share by Players in 2022
Figure 22. PD-L1 and PIK3CA Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players PD-L1 and PIK3CA Testing Market Share in 2022
Figure 24. Global Top 6 Players PD-L1 and PIK3CA Testing Market Share in 2022
Figure 25. Global PD-L1 and PIK3CA Testing Consumption Value Share by Type (2018-2023)
Figure 26. Global PD-L1 and PIK3CA Testing Market Share Forecast by Type (2024-2029)
Figure 27. Global PD-L1 and PIK3CA Testing Consumption Value Share by Application (2018-2023)
Figure 28. Global PD-L1 and PIK3CA Testing Market Share Forecast by Application (2024-2029)
Figure 29. North America PD-L1 and PIK3CA Testing Consumption Value Market Share by Type (2018-2029)
Figure 30. North America PD-L1 and PIK3CA Testing Consumption Value Market Share by Application (2018-2029)
Figure 31. North America PD-L1 and PIK3CA Testing Consumption Value Market Share by Country (2018-2029)
Figure 32. United States PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe PD-L1 and PIK3CA Testing Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe PD-L1 and PIK3CA Testing Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe PD-L1 and PIK3CA Testing Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 39. France PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific PD-L1 and PIK3CA Testing Consumption Value Market Share by Region (2018-2029)
Figure 46. China PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 49. India PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 52. South America PD-L1 and PIK3CA Testing Consumption Value Market Share by Type (2018-2029)
Figure 53. South America PD-L1 and PIK3CA Testing Consumption Value Market Share by Application (2018-2029)
Figure 54. South America PD-L1 and PIK3CA Testing Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa PD-L1 and PIK3CA Testing Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa PD-L1 and PIK3CA Testing Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa PD-L1 and PIK3CA Testing Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE PD-L1 and PIK3CA Testing Consumption Value (2018-2029) & (USD Million)
Figure 63. PD-L1 and PIK3CA Testing Market Drivers
Figure 64. PD-L1 and PIK3CA Testing Market Restraints
Figure 65. PD-L1 and PIK3CA Testing Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of PD-L1 and PIK3CA Testing in 2022
Figure 68. Manufacturing Process Analysis of PD-L1 and PIK3CA Testing
Figure 69. PD-L1 and PIK3CA Testing Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
